Advertisement

Topics

Alnylam hopes for 2018 filing for RNAi liver disease drug

08:20 EDT 16 Apr 2018 | pharmaphorum

Alnylam is hoping to file a second RNA interference (RNAi) drug with the FDA by the end of 2018 after unveiling encouraging early-stage data for givosiran in a rare liver disease. The technology uses small strands of RNA to silence or interfere wi...

Original Article: Alnylam hopes for 2018 filing for RNAi liver disease drug

NEXT ARTICLE

More From BioPortfolio on "Alnylam hopes for 2018 filing for RNAi liver disease drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...